CN105561298A - 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 - Google Patents

神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 Download PDF

Info

Publication number
CN105561298A
CN105561298A CN201410550212.7A CN201410550212A CN105561298A CN 105561298 A CN105561298 A CN 105561298A CN 201410550212 A CN201410550212 A CN 201410550212A CN 105561298 A CN105561298 A CN 105561298A
Authority
CN
China
Prior art keywords
heart failure
ejection fraction
neuregulin
nrg
preserved ejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410550212.7A
Other languages
English (en)
Chinese (zh)
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to CN202010283482.1A priority Critical patent/CN111407882A/zh
Priority to CN201410550212.7A priority patent/CN105561298A/zh
Priority to JP2017520447A priority patent/JP2017532343A/ja
Priority to KR1020177010326A priority patent/KR102603711B1/ko
Priority to CN201580054201.2A priority patent/CN108064164A/zh
Priority to PCT/CN2015/091459 priority patent/WO2016058493A1/zh
Priority to ES15850529T priority patent/ES2924395T3/es
Priority to EP15850529.7A priority patent/EP3207940B1/en
Priority to RU2017116973A priority patent/RU2017116973A/ru
Priority to AU2015333335A priority patent/AU2015333335B2/en
Priority to CA2963322A priority patent/CA2963322A1/en
Priority to EP22174662.1A priority patent/EP4112068A1/en
Priority to US15/518,730 priority patent/US10561709B2/en
Priority to KR1020237039263A priority patent/KR20230159650A/ko
Publication of CN105561298A publication Critical patent/CN105561298A/zh
Priority to US16/714,397 priority patent/US20200368317A1/en
Priority to JP2020139931A priority patent/JP2020193217A/ja
Priority to AU2021258063A priority patent/AU2021258063B2/en
Priority to US17/558,451 priority patent/US20220354928A1/en
Priority to JP2022108771A priority patent/JP2022153417A/ja
Priority to JP2024135192A priority patent/JP2024164068A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201410550212.7A 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 Pending CN105561298A (zh)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CN202010283482.1A CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AU2015333335A AU2015333335B2 (en) 2014-10-17 2015-10-08 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
EP22174662.1A EP4112068A1 (en) 2014-10-17 2015-10-08 Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
CN201580054201.2A CN108064164A (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
PCT/CN2015/091459 WO2016058493A1 (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
ES15850529T ES2924395T3 (es) 2014-10-17 2015-10-08 Métodos y composiciones de una neurregulina para prevenir, tratar o retrasar la insuficiencia cardíaca con fracción de eyección preservada
EP15850529.7A EP3207940B1 (en) 2014-10-17 2015-10-08 Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
RU2017116973A RU2017116973A (ru) 2014-10-17 2015-10-08 Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
JP2017520447A JP2017532343A (ja) 2014-10-17 2015-10-08 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
CA2963322A CA2963322A1 (en) 2014-10-17 2015-10-08 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
KR1020177010326A KR102603711B1 (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법
US15/518,730 US10561709B2 (en) 2014-10-17 2015-10-08 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
KR1020237039263A KR20230159650A (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법
US16/714,397 US20200368317A1 (en) 2014-10-17 2019-12-13 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
JP2020139931A JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
AU2021258063A AU2021258063B2 (en) 2014-10-17 2021-10-29 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
US17/558,451 US20220354928A1 (en) 2014-10-17 2021-12-21 Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
JP2022108771A JP2022153417A (ja) 2014-10-17 2022-07-06 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2024135192A JP2024164068A (ja) 2014-10-17 2024-08-14 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010283482.1A Division CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Publications (1)

Publication Number Publication Date
CN105561298A true CN105561298A (zh) 2016-05-11

Family

ID=55746124

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010283482.1A Pending CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7A Pending CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201580054201.2A Pending CN108064164A (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010283482.1A Pending CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580054201.2A Pending CN108064164A (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Country Status (10)

Country Link
US (3) US10561709B2 (https=)
EP (2) EP3207940B1 (https=)
JP (4) JP2017532343A (https=)
KR (2) KR20230159650A (https=)
CN (3) CN111407882A (https=)
AU (2) AU2015333335B2 (https=)
CA (1) CA2963322A1 (https=)
ES (1) ES2924395T3 (https=)
RU (1) RU2017116973A (https=)
WO (1) WO2016058493A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166218A (zh) * 2018-04-11 2021-07-23 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
WO2021169845A1 (zh) * 2020-02-24 2021-09-02 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN113677699A (zh) * 2019-04-01 2021-11-19 伊莱利利公司 神经调节蛋白-4化合物和使用方法
WO2024067817A1 (zh) * 2022-09-30 2024-04-04 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物
CN102159236A (zh) * 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN102470161A (zh) * 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
CN103857695A (zh) * 2011-10-10 2014-06-11 上海泽生科技开发有限公司 治疗心力衰竭的组份和方法
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU2001241839A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
JP2007505158A (ja) 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
WO2006108208A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2370458B1 (en) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin peptides and their use
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物
CN102159236A (zh) * 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN102470161A (zh) * 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
CN103857695A (zh) * 2011-10-10 2014-06-11 上海泽生科技开发有限公司 治疗心力衰竭的组份和方法
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
TARONE G等: "Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology", 《EUR J HEART FAIL》 *
TSCHÖPE C等: "New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction", 《CURR HEART FAIL REP》 *
刘宁: "随机、双盲、多中心、标准治疗基础上的安慰剂并行对照评价注射用重组人纽兰格林对慢性收缩性心力衰竭患者疗效与安全性的Ⅱ期临床观察", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 *
苏丽军等: "Neuregulin 治疗慢性心力衰竭的研究进展", 《临床心血管病杂志》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166218A (zh) * 2018-04-11 2021-07-23 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
CN113166218B (zh) * 2018-04-11 2024-08-13 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
CN113677699A (zh) * 2019-04-01 2021-11-19 伊莱利利公司 神经调节蛋白-4化合物和使用方法
CN113677699B (zh) * 2019-04-01 2024-06-11 伊莱利利公司 神经调节蛋白-4化合物和使用方法
WO2021169845A1 (zh) * 2020-02-24 2021-09-02 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
WO2024067817A1 (zh) * 2022-09-30 2024-04-04 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Also Published As

Publication number Publication date
RU2017116973A (ru) 2018-11-19
KR20230159650A (ko) 2023-11-21
KR102603711B1 (ko) 2023-11-20
EP4112068A1 (en) 2023-01-04
AU2015333335A1 (en) 2017-04-20
EP3207940A4 (en) 2018-06-06
US20170232068A1 (en) 2017-08-17
JP2017532343A (ja) 2017-11-02
US10561709B2 (en) 2020-02-18
KR20170066440A (ko) 2017-06-14
US20220354928A1 (en) 2022-11-10
AU2021258063B2 (en) 2025-02-27
WO2016058493A1 (zh) 2016-04-21
RU2017116973A3 (https=) 2019-05-06
AU2021258063A1 (en) 2021-11-25
CN111407882A (zh) 2020-07-14
JP2024164068A (ja) 2024-11-26
EP3207940A1 (en) 2017-08-23
JP2020193217A (ja) 2020-12-03
US20200368317A1 (en) 2020-11-26
EP3207940B1 (en) 2022-06-01
JP2022153417A (ja) 2022-10-12
ES2924395T3 (es) 2022-10-06
CN108064164A (zh) 2018-05-22
CA2963322A1 (en) 2016-04-21
AU2015333335B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
AU2021258063B2 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
JP7761964B2 (ja) 心不全の治療用組成物
US12208158B2 (en) Extended release of neuregulin for treating heart failure
EP3199174B1 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
EP2440236B1 (en) Neuregulin based methods for treating heart failure
JP2025060703A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
CN110835368A (zh) 神经调节蛋白多肽片段及其用途
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
WO2024067817A1 (zh) 神经调节蛋白及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CB02 Change of applicant information

Address after: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68

Applicant after: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, Co.,Ltd.

Address before: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68

Applicant before: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160511

RJ01 Rejection of invention patent application after publication